Johns Hopkins Emergency Department finds more appropriate antibiotic treatment and shorter STI visits Read more

10/21/2021

•    2021Press Release

Visby Medical Appoints Industry Veteran John W. Kuo as Chief Legal Officer

Visby Medical™, a leading medical diagnostic company, today announced the appointment of John W. Kuo as the company’s new Chief Legal Officer. An experienced veteran in corporate law, Kuo brings more than 30 years of experience across multiple industries, including nearly 20 years in the healthcare industry.

(SAN JOSE, CA), October 21, 2021 – Visby Medical™, a leading medical diagnostic company, today announced the appointment of John W. Kuo as the company’s new Chief Legal Officer. An experienced veteran in corporate law, Kuo brings more than 30 years of experience across multiple industries, including nearly 20 years in the healthcare industry. In his new role, Kuo will lead legal strategy on all corporate initiatives and provide counsel to the executive leadership team and board of directors.

“I am pleased to welcome John to the Visby team,” said Visby Medical Founder and CEO Adam de la Zerda. “Our company has grown exponentially since launching our flagship COVID-19 and Women’s Sexual Health diagnostics, and John’s expertise will be an invaluable asset to the company as we move forward.”

Most recently, Kuo served as Executive Vice President of General Counsel and Chief Compliance Officer at Charles River Laboratories where he was responsible for overseeing legal, compliance, privacy, regulatory and security functions.  Previously, he was Senior Vice President, General Counsel and Corporate Secretary at Varian Medical Systems for over 15 years.  Prior to that, he held leadership positions at BroadVision and 3Com Corporation.  He also serves as the board for Mirion Technologies and several non-profit boards, including UC Berkeley Law’s Alumni Association, the Law Foundation of Silicon Valley, the Asian Pacific Fund and the Cornell University Council.

“Visby’s proprietary technology has the potential to be a real-world solution for diagnosing and treating infectious diseases,” said Kuo. “I look forward to playing an essential role in an organization focused on accelerating the field of diagnostics.”

Kuo has been recognized with multiple awards, including “Lifetime Achievement Award” by the Silicon Valley Business Journal, “Legal Department of the Year” by The Recorder and “Legend in Law” by the Burton Foundation. He began practicing law as an associate attorney with Norton Rose Fulbright in Houston after attending UC Berkeley School of Law and Cornell University.

About Visby Medical™

Visby Medical is a diagnostics company that is transforming the order of diagnosis and treatment for infectious diseases. The Company’s proprietary technology development program culminated in the world’s first instrument-free, single-use PCR platform that fits in the palm of your hand and rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. The Visby Medical technology is also helping to fight the global pandemic via the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. Visby Medical is accelerating the delivery of fast and accurate, palm-sized PCR diagnostics to the point of care, and eventually for use at home.

For more information, visit www.visbymedical.com. Follow Visby Medical on LinkedIn at www.linkedin.com/company/visbymedical; Facebook, Instagram, and Twitter @VisbyMedical.

Contact: (240) 839-0945 | press@visby.com

Read more articles & insights

Visby Medical™ Sexual Health Test Results in More Appropriate Antibiotic Treatment and Shorter Emergency Department Visits Than Standard of Care

Point-of-Care test significantly shortens time from ED arrival to test results, treatment and discharge – significant improvements are seen in the use of antibiotics for the treatment of chlamydia and gonococcal infections in women. Nationwide increases in sexually transmitted diseases and antibiotic resistance create the need for a paradigm shift from traditional lab-based molecular testing.

Read More